Cardiology

Nonadherence to statins plus ACEIs/ARBs risky post MI

(HealthDay)—Nonadherence to angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs) and/or statins following acute myocardial infarction (AMI) is associated with higher mortality, according ...

Cardiology

Evolocumab doesn't affect cognition when added to statins

(HealthDay)—There is no significant difference in cognitive function for patients treated with evolocumab or placebo added to statin therapy, according to a study published in the Aug. 17 issue of the New England Journal ...

Cardiology

Quitting statins after stroke may raise risk of another stroke

Stroke patients who stopped taking statin drugs three to six months after a first ischemic stroke, the type caused by narrowed arteries, had a higher risk of a having another stroke within a year, according to new research ...

Cardiology

Continuing statin after adverse Rx tied to lower cardiac risk

(HealthDay)—For patients with an adverse reaction to a statin, continued statin prescriptions are associated with lower incidence of cardiovascular events and death, according to a study published online July 25 in the ...

Cardiology

Benefits of continued statin use after adverse reactions

Statins are known to reduce the risk of death and cardiovascular events for people who are at high risk; however, as many as 75 percent of patients discontinue statin therapy within two years, often after reporting an adverse ...

Cardiology

Estimating cost when it comes to novel therapies

When it comes to patient care, finding the best treatment can sometimes include finding an equal, yet more economical solution. Rather than introducing a costly new medication, for some patients changing current dosages or ...

page 5 from 14